Axsome Therapeutics (AXSM) Finished Goods (2022 - 2026)

Axsome Therapeutics' Finished Goods history runs 5 years deep, the most recent figure standing at $15.9 million for Q1 2026.

• In Q1 2026, Finished Goods rose 77.28% year-over-year to $15.9 million; the TTM figure through Mar 2026 stood at $15.9 million (up 77.28% YoY), while the FY2025 annual figure was $11.3 million, up 25.53% from the prior year.
• Finished Goods came in at $15.9 million for Q1 2026 at Axsome Therapeutics, up from $11.3 million in the prior quarter.
• In the past five years, Finished Goods ranged from a high of $15.9 million in Q1 2026 to a low of $1.6 million in Q4 2022.
• A 5-year average of $8.7 million and a median of $9.0 million in 2025 frame the typical range for Finished Goods.
• Across the five-year window, Finished Goods soared 506.48% in 2023 and retreated 12.0% in 2025, its largest moves.
• Axsome Therapeutics' Finished Goods stood at $1.6 million in 2022, then jumped by 506.48% to $9.6 million in 2023, then decreased by 6.81% to $9.0 million in 2024, then advanced by 25.53% to $11.3 million in 2025, then jumped by 40.85% to $15.9 million in 2026.
• According to Business Quant data, Finished Goods over the past three periods registered $15.9 million, $11.3 million, and $10.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison